VeriSIM Life and Mayo Clinic Team Up to Co-develop New Therapies
VeriSIM Life and Mayo Clinic are collaborating to develop new promising drug candidates.
VeriSIM Life (VeriSIM), a US-based artificial intelligence (AI)-enabled company that provides drug discovery and drug development services, has entered into a collaboration with Mayo Clinic to improve the preclinical translation of promising drug candidates for development.
Under the agreement, VeriSIM will use its proprietary BIOiSIM platform and Translational Index technology to reduce the number of outsourced preclinical experiments. These platforms are also expected to help de-risk R&D decisions early on to ensure expedited development of novel, safe, and highly efficacious drugs, according to a June 28, 2022 company press release. Mayo Clinic physician researchers will work with VeriSIM in key disease areas, including oncology, hematology, bone/joint-disorders, and neurological diseases.
“This collaboration will explore the full potential of our combined approach to developing best-in-class drug candidates to serve patients’ unmet needs,” said Jo Varshney, founder and CEO of VeriSIM Life, in the press release.
Source: VeriSIM Life
A Novel, Enhanced, and Sustainable Approach to Audit Trail Review
July 4th 2025Eli Lilly and Company developed an innovative and sustainable approach to audit trail review (ATR) aimed at reducing the ATR burden while adhering to regulatory expectations and data integrity (DI) principles. The process has transformed employees' understanding of ATR and complemented the DI by design approach, leading to better system designs that meet expected controls and reduce non-value-added data reviews.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
